CTXR:NASDAQ, Citius Pharmaceuticals, Inc.
Why CTXR stock rose on October 27
Citius Pharmaceuticals, Inc. rose 11.6%
on Tuesday, October 27, 2026, on 521,722 shares.
Headlines around the move:
CTXR stock overview
Citius Pharmaceuticals, Inc. (CTXR:NASDAQ) closed at $0.541 on October 28, 2026,
up 7.90% on the day.
The stock trades 67.0% below its 52-week high of $1.64
and 46.2% above its 52-week low of $0.370.
Over the past year, it lost 64.2%.
Citius Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
Key figures
- Price
- $0.541
- Day change
- +7.90%
- Volume
- 201,084
- Average volume
- 505,810
- Market cap
- 14M+
- 52-week range
- $0.370 – $1.64
- 50-day average
- $0.539
- 200-day average
- $0.660
Price action over the past year
In 252 trading sessions since October 28, 2025, CTXR closed higher on 107 days (42%).
Its best day was March 31, 2026 (+32.35%) and its worst was August 17, 2026 (-25.66%).
The stock moved 10% or more in a single session 31 times.
It opened at least 5% above the previous day's high 2 times.
Recent signals
CTXR news
-
Oct 26, 2026:
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
-
Oct 26, 2026:
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
-
Oct 12, 2026:
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
-
Sep 3, 2026:
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
-
Aug 14, 2026:
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
-
Aug 14, 2026:
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
-
Aug 12, 2026:
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
-
Aug 5, 2026:
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals Inc is a specialty pharmaceutical company engaged in development and commercialization of therapeutic products for markets using patented or proprietary formulations and modified drug delivery technology.
Similar stocks
Find more stocks like CTXR with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.